American Family Ventures and GV have exited property rental platform developer Cozy in a $68m acquisition by CoStar that followed about $18m in funding.
University of Southampton spinout Exosect has been put up for sale by Hilco Streambank in an effort to salvage the pest and disease control technology producer.
Merck & Co, Accenture and UPS are all set to exit application integration and data management platform developer Liaison Technologies through the acquisition.
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
A round up of all the latest news on www.globalcorporateventuring.com for our subscribers
Illumina, WuXi PharmaTech, Kangmei and Institut Mérieux-backed synthetic DNA producer Twist Bioscience floated at the bottom of its range.
UCL Technology Fund-backed gene therapy developer Orchard Therapeutics raised $200m in an offering that could possibly close at $230m.
GSK, Sphera Global and Medison-backed gene therapy developer Orchard Therapeutics raised $200m in an offering that could possibly close at $230m.
Stanford-StartX Fund has exited business intelligence software provider DataFox in an acquisition of undisclosed size by Oracle.
The Legend Capital-backed sacral neuromodulation device developer floated in the middle of its range while upping the number of shares in the IPO.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
